Amphastar Pharmaceuticals, Inc. (AMPH) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $21.38. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of AMPH = $35.53 (+66.2% from the current price, the stock appears undervalued). Analyst consensus target is AMPH = $30 (+40.3% upside).
Valuation: AMPH trades at a trailing Price-to-Earnings (P/E) of 9.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.55.
Financials: revenue is $720M, +13.6%/yr average growth. Net income is $98M, growing at +9.3%/yr. Net profit margin is 13.6% (healthy). Gross margin is 49.5% (-0.4 pp trend).
Balance sheet: total debt is $656M against $789M equity (Debt-to-Equity (D/E) ratio 0.83, moderate). Current ratio is 4.02 (strong liquidity). Debt-to-assets is 40.3%. Total assets: $1.6B.
Analyst outlook: 6 / 12 analysts rate AMPH as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 84/100 (Pass), Growth 73/100 (Pass), Past 100/100 (Pass), Health 67/100 (Partial), Moat 53/100 (Partial), Future 64/100 (Pass), Income 55/100 (Partial).
